

1 TITLE: Epstein-Barr Virus DNAemia and Post-Transplant Lymphoproliferative Disorder in Pediatric Solid
2 Organ Transplant Recipients

3
4 AUTHORS: Yeh-Chung Chang¹, Rebecca R. Young¹, Alisha M. Mavis², Eileen T. Chambers³, Sonya Kirmani⁴,
5 Matthew S. Kelly¹, Ibukunoluwa C. Kalu¹, Michael J. Smith¹, Debra J. Lugo¹

6
7 AFFILIATIONS

8 ¹Department of Pediatrics, Division of Infectious Diseases, Duke University School of Medicine, Durham,
9 North Carolina, United States of America;

10 ²Department of Pediatrics, Division of Gastroenterology, Duke University School of Medicine, Durham,
11 North Carolina, United States of America;

12 ³Department of Pediatrics, Division of Nephrology, Duke University School of Medicine, Durham, North
13 Carolina, United States of America;

14 ⁴Department of Pediatrics, Division of Cardiology, Duke University School of Medicine, Durham, North
15 Carolina, United States of America

16
17 CORRESPONDING AUTHOR ORCID: 0000-0003-3073-4980

18 CORRESPONDING AUTHOR AND EMAIL: Yeh-Chung Chang, dan.chang@duke.edu

19 The Duke University Health System Institutional Review Board of the Duke University School of Medicine
20 gave ethical approval for this work.

21 Abstract

22 Background: Pediatric solid organ transplant (SOT) recipients commonly have Epstein-Barr virus (EBV)
23 DNAemia and are at risk of developing post-transplant lymphoproliferative disorder (PTLD). EBV
24 DNAemia has not been analyzed on a continuous scale in this population.

25 Methods: All children ≤ 18 years of age who underwent SOT at a single center between January 1, 2007
26 and July 31, 2018 were included in this retrospective study. Transplant episodes in which PTLD occurred
27 were compared to transplant episodes without PTLD. Multivariable logistic regression was used to
28 identify factors associated with the development of EBV DNAemia and maximum height of EBV
29 DNAemia. A Cox proportional hazards model was used to calculate hazard ratios for time to PTLD.

30 Results: Of 275 total transplant recipients and 294 transplant episodes, there were 14 episodes of PTLD.
31 Intestinal and multivisceral transplant were strongly associated with PTLD ($p=0.002$). Risk factors for the
32 development of EBV DNAemia include donor and recipient positive EBV serologies ($p=0.001$) and older
33 age ($p=0.001$). Maximum level of EBV DNAemia was significantly associated with development of PTLD
34 ($p<0.0001$). Every one log (\log_{10}) increase in the maximum level of EBV DNAemia was associated with a
35 more than doubling of the hazard on developing PTLD (HR: 2.18, 95% CI 1.19-3.99).

36 Conclusions: Transplant type was strongly associated with development of PTLD in pediatric SOT
37 recipients. EBV serologies and age were associated with the development of EBV DNAemia and height of
38 DNAemia. High levels of EBV DNAemia were strongly associated with an increased hazard of PTLD.

39

40

41

42

43 Introduction

44 Post-transplant lymphoproliferative disorder (PTLD) is a significant cause of morbidity and mortality in
45 pediatric solid organ transplantation (SOT) recipients. Epstein-Barr Virus (EBV) DNAemia plays a key role
46 in the pathophysiology of EBV-related PTLD but characteristics of pediatric SOT recipients who develop
47 EBV DNAemia and patterns of EBV DNAemia have not been well defined.¹ Many centers monitor EBV
48 DNAemia with established protocols for interventional measures such as decreasing
49 immunosuppression.² These protocols may differ between centers and between different types of organ
50 transplant recipients.³ More data is needed to guide clinical decisions in specific scenarios.

51 There have been many studies on risk factors for PTLD in SOT recipients.¹⁻⁴ Overall, risk factors for
52 development of PTLD within the first 12 months of transplant (early PTLD) include: type of transplant, T-
53 cell depleting therapies such as anti-thymocyte globulin (ATG), and young age. Early PTLD is also strongly
54 influenced by donor and recipient serologies as donor-derived EBV infection is a strong risk factor for
55 PTLD. Risk factors for development of PTLD after 12 months post-transplant (late PTLD) include length
56 and duration of immunosuppression, and type of organ transplanted. Intestinal transplant recipients
57 have been found to have the highest risk for PTLD, followed by lung, then heart, then liver, and lastly,
58 kidney transplant recipients.

59 There is a higher incidence of PTLD in pediatric SOT recipients when compared to adult SOT recipients.¹
60 One reason is that primary EBV infection has a higher risk of causing PTLD.⁴ One pediatric SOT study
61 found EBV viral load was significantly higher in cases of PTLD, when matched to controls.⁵ Another study
62 reviewing only pediatric patients found the following risk factors to be significant in a univariate model:
63 age at transplant, use of basiliximab, steroid intensification, ATG, median peak EBV value level, and
64 chronically elevated EBV DNAemia.⁶ However, in the multivariable model, only age, use of steroids, and
65 peak EBV value were significant.

66 Many previous studies in pediatric solid organ transplants have categorized EBV DNAemia into three
67 categories: 1) chronic high load (CHL) carriers, 2) chronic low viral load carriers, and 3) sustained
68 undetectable EBV levels, with chronic defined as a time period > 6 months.⁷⁻¹⁰ In pediatric heart
69 transplant recipients, CHL carriers are predisposed to PTLD, and pediatric intestinal transplant recipients
70 are at intermediate risk.^{7,8} In the pediatric liver and kidney populations, CHL carriers are not at higher
71 risk of PTLD.^{9,10} Despite low sample sizes within studies, this difference suggests that transplant type and
72 immunosuppression play a large role in the development of PTLD.

73 There have been many studies on trying to categorize cutoffs for EBV DNAemia and risk for PTLD, as well
74 as establishing a predictive model for PTLD.^{6,11,12} While many of these studies have tried to categorize a
75 certain EBV quantitative cutoff level for when patients are at risk for PTLD, there are confounding risk
76 factors such as patient age, type of transplant and type of immunosuppression and not all models have
77 been well validated.

78 The epidemiology of PTLD has been changing in recent years.^{13,14} In addition, EBV monitoring has
79 provided a wealth of data that has not been studied in a detailed manner. While EBV DNAemia has been
80 categorized in previous studies, it has not yet been studied on a continuous scale and available pediatric
81 literature has not linked maximum height of EBV DNAemia to PTLD on a granular level. Therefore, we
82 undertook a comprehensive retrospective descriptive study at a large pediatric SOT center to specifically
83 evaluate risk factors associated with EBV DNAemia. We also wanted to investigate the predictive value
84 of continuous EBV monitoring for PTLD in order to demonstrate its ongoing utility.

85

86 Material and Methods

87 We performed a retrospective study of patients ≤ 18 years of age who received a solid organ transplant
88 at Duke University Medical Center between January 1, 2007 and July 31, 2018. Events were recorded by

89 transplant episode. The population included heart, kidney, liver, lung, intestinal, and multivisceral
90 transplant recipients. Characterization of the pediatric SOT population was performed using the United
91 Network for Organ Sharing (UNOS) database, and data was also extracted from the center's electronic
92 health records using the program Duke Enterprise Data Unified Content Explorer (DEDUCE).¹⁵ The
93 diagnosis of PTLD was identified by diagnosis code and verified through chart review of pathology
94 results and progress notes in the electronic health record.

95 At our center, each pediatric solid organ transplant program has developed their own methods of
96 screening for EBV DNAemia. However, in general, quantitative whole blood EBV polymerase chain
97 reaction (PCR) studies are done monthly for the first year post-transplant, then spaced out to every 3
98 months for the second and third year post-transplant, then either every 6 months or yearly afterwards if
99 there are no issues. If EBV DNAemia is detected, quantitative PCRs are obtained more frequently.

100 EBV DNAemia values were extracted from the electronic health record, including accompanying chart
101 review for missing values. For most of the study period, the quantitative unit of EBV DNAemia was
102 reported as copies/ μ L. Starting in mid-2017, this was changed to international units/mL (IU/mL), and a
103 conversion factor was used to normalize these values in concordance with the previous quantification.
104 Patients who developed EBV DNAemia after transplant were compared to patients who did not develop
105 DNAemia. Logistic regression was performed with the variables of age, race, type of transplant, type of
106 induction immunosuppression, and donor and recipient EBV serology.

107 EBV DNAemia was defined as any detection of EBV virus by quantitative polymerase reaction (PCR). EBV
108 donor and recipient serologies were based on what was entered into the patient's chart at time of
109 transplant. Demographic and clinical characteristics were compared between the two groups, using Chi
110 square and Fisher's exact tests for categorical factors and Mann-Whitney U tests for continuous factors.

111 The diagnosis of PTLD was confirmed by chart review. All cases of PTLD had accompanying histologic
112 diagnoses which included EBER staining and description of atypical cells seen on pathology. Sources of
113 biopsy tissue included lymph nodes, tonsils and adenoids, and the transplanted organ.

114 For the analysis of the height of EBV DNAemia, the maximum single EBV value was identified. That value
115 was then \log_{10} transformed and an analysis of covariance (ANCOVA) was used to evaluate associations
116 between the maximum EBV value and demographic and clinical factors. After categorization and taking
117 the average of the \log_{10} transformed values, the data was back transformed, establishing the geometric
118 mean. Logarithmic comparison of quantitative EBV values has been well described in the literature.^{16,17}

119 A Cox proportional hazards model was used to link clinical risk factors to time to PTLD. The event of
120 PTLD, death, and the event of a subsequent transplant were used as censoring criteria. The last
121 observed value was carried forward. A robust variance (sandwich) estimator was used to control for the
122 fact that some children were included more than once, due to multiple transplants. Adjusted models
123 incorporated variables that were significant in the unadjusted model as well as risk factors that were
124 denoted to be clinically significant a priori.

125

126 Results

127 We reviewed 275 pediatric patients who underwent 294 transplant episodes (Table 1). The median
128 (interquartile range) age of patients was 4 (IQR 0, 14) years. The most common transplant type was liver
129 (46%), followed by heart (25%), kidney (13%), multivisceral (7%), lung (7%), and intestinal (3%). For EBV
130 serologies, donor positive/recipient negative (D+/R-) and donor positive/recipient positive (D+/R+) were
131 the most common (33% and 31% respectively), followed by donor negative/recipient negative (D-/R-)
132 (14%), and then donor negative/recipient positive (D-/R+) (11%), with the remaining unknown (11%). A

- 133 total of 55 children (18.7%) received T cell depleting therapy including anti-thymocyte globulin (ATG) or
 134 alemtuzumab (Campath) at induction.

Table 1: Characteristics of all children in the study, regardless of PTLD or EBV status

		n	%
Total number of transplants		294	
Total number of children		275	
Race/Ethnicity			
	American Indian or Alaska Native	3	1.1%
	Asian	6	2.2%
	Black	84	30.6%
	Hispanic	35	12.7%
	Multiracial	6	2.2%
	White	141	51.3%
Gender			
	Male	148	53.8%
	Female	127	46.2%
Transplant Type			
	Heart	73	24.8%
	Intestine	10	3.4%
	Kidney	38	12.9%
	Liver	134	45.6%
	Lung	19	6.5%
	Multivisceral	20	6.8%
EBV Serology at Transplant			
	D+/R+	98	33.3%
	D+/R-	92	31.3%
	D-/R+	32	10.9%
	D-/R-	40	13.6%
	Unknown	32	10.9%
Transplant Number			
	First	274	93.2%
	Second	16	5.4%
	Third	4	1.4%
EBV Status Post Transplant			
	EBV Positive	160	54.4%
	EBV Negative	111	37.8%
	No testing	23	7.8%
Induction Immunosuppression			
	ATG or high dose steroids	55	18.7%
	Not ATG or high dose steroids	231	78.6%

	Missing	8	2.7%
		median	(p25, p75)
Year of Transplant		2013	(2011, 2016)
Age at Transplant (years)		4	(0, 14)

135

136 All children who developed PTLD were EBV positive, and thus, only EBV positive children were included

137 in following analyses (Table 2). Fourteen children developed PTLD after transplant, for an overall

138 incidence rate of 4.8%. Transplant type was significantly associated with PTLD ($p=0.001$). Intestinal and

139 multivisceral transplant recipients accounted for 21% and 14% of PTLD cases respectively, while only

140 accounting for 2% and 3% of the total population that was EBV positive. There was also an association

141 between PTLD and race ($p=0.04$) as there were a total of six Asian children in the study who were EBV

142 positive, and two developed PTLD. Asian children comprised 14% of the PTLD cases, but only 2.2% of the

143 study population. Induction immunosuppression and age were not associated with PTLD in our study

144 ($p=0.18$ and $p=0.17$, respectively). For the nine patients who developed PTLD within the first year, EBV

145 values were plotted over time (Figure 1). For most patients, the general pattern was a steady increase in

146 EBV values, followed by diagnosis of PTLD, and then a rapid decline.

Table 2. The characteristics of children who had PTLD at any time post-transplant are compared to children who had no PTLD. This is limited to the children who had any EBV DNAemia after transplant. The incidence of PTLD is shown for each demographic group.

	PTLD		No PTLD		p-value
	n	%	n	%	
Total	14		146		
Type of Transplant					
Heart	1	7.1%	36	24.7%	0.001**
Intestine	3	21.4%	3	2.1%	
Kidney	3	21.4%	22	15.1%	
Liver	4	28.6%	77	52.7%	
Lung	1	7.1%	3	2.1%	
Multivisceral	2	14.3%	5	3.4%	
EBV Serology at Transplant					
D+/R+	4	28.6%	53	36.3%	0.47

D+/R-	4	28.6%	56	38.4%	
D-/R+	1	7.1%	14	9.6%	
D-/R-	2	14.3%	10	6.8%	
Unknown	3	21.4%	13	8.9%	
Race/Ethnicity					
American Indian/Alaskan	0	0%	5	3.4%	0.04**
Asian	2	14.3%	2	1.4%	
Black	2	14.3%	50	34.2%	
Hispanic	3	21.4%	19	13.0%	
Multiracial	0	0%	4	2.7%	
White	7	50.0%	66	45.2%	
Gender					
Female	3	21.4%	67	45.9%	0.078
Male	11	78.6%	79	54.1%	
Transplant Number					
1	14	100%	133	91.1%	0.51 ⁺
2	0	0%	10	6.9%	
3	0	0%	3	2.1%	
Induction Immunosuppression					
ATG or High Dose Steroids	4	28.6%	26	15.4%	0.18
Not ATG or High Dose Steroids	9	64.3%	136	80.5%	
Unknown/Missing	1	7.1%	7	4.1%	
Age (years) at transplant					
Median (!QR)		2 (0, 9)		4 (0, 14)	0.17

*p<0.05

+ By Fisher's-Exact Test

147

148 Risk factors for EBV DNAemia were examined (Table 3). Significant risk factors for EBV DNAemia
 149 included: EBV serology at the time of transplant, age, and type of transplant in the unadjusted model,
 150 and only EBV serology and age in the adjusted model (Table 4). Heart transplant recipients were at
 151 lower odds for EBV DNAemia, with OR 0.44 (95% CI 0.22-0.89). Lung transplant recipients were similarly
 152 at lower odds, but sample size was limited. Donor positive/recipient negative (D+/R-) and donor
 153 positive/recipient positive (D+/R+) transplant recipients were at increased odds of developing EBV
 154 DNAemia compared to donor negative/recipient negative (D-/R-) transplant recipients, with OR 3.90

155 (95% CI 1.55-9.80), and OR 4.83 (95% CI 2.02-11.55), respectively. Older children were also associated

156 with an increased risk, with every one year increase in age associated with an OR of 1.10 (1.04-1.16).

157 Table 3. The characteristics of children who had any EBV DNAemia after transplant are compared to
 158 those who did not have any EBV DNAemia

159

		EBV		No EBV		p-value
		n	%	n	%	
Total		160	59%	111	41%	
Type of Transplant						
	Heart	37	23.1%	31	27.9%	0.14 ⁺
	Intestine	6	3.8%	3	2.7%	
	Kidney	25	15.6%	12	10.8%	
	Liver	81	50.6%	47	42.3%	
	Lung	4	2.5%	7	6.3%	
	Multivisceral	7	4.4%	11	9.9%	
EBV Serology at Transplant						
	D+/R+	57	35.6%	29	26.1%	0.001*
	D+/R-	60	37.5%	28	25.2%	
	D-/R+	15	9.4%	15	13.5%	
	D-/R-	12	7.5%	26	23.4%	
	Unknown	16	10.0%	13	11.7%	
Race						
	American Indian/Alaskan	5	3.1%	0	0.0%	0.11
	Asian	4	2.5%	0	0.0%	
	Black	52	32.5%	33	29.7%	
	Hispanic	22	13.8%	14	12.6%	
	Multiracial	4	2.5%	1	0.9%	
	White	73	45.6%	63	56.8%	
Sex						
	Female	70	43.8%	50	45.0%	0.83
	Male	90	56.3%	61	55.0%	
Transplant Number						
	1	147	91.9%	106	95.5%	0.28
	2	10	6.3%	5	4.5%	
	3	3	1.9%	0	0.0%	
Induction Immunosuppression						
	ATG or High Dose Steroids	27	17.0%	25	22.5%	0.26
	Not ATG or High Dose Steroids	131	83.0%	86	77.5%	

	median	(p25, p75)	median	(p25, p75)	
Year of Transplant	2014	(2011, 2016)	2012	(2010, 2015)	0.58
Age at Transplant (years)	7	(1, 14)	1	(0, 10)	0.001*

*p<0.05

+By Fisher's-Exact Test

160

161 Table 4. The association between demographic characteristics and EBV DNAemia. Only significant risk
162 factors are included in this table.

	EBV (n)	No EBV (n)	p-value	OR of EBV DNAemia (95% CI)	p-value
Total	160	111			
Type of Transplant					
Heart	37	31	0.14	0.44 (0.22, 0.89)	0.02
Intestine	6	3		2.07 (0.44, 9.76)	0.36
Kidney	25	12		0.57 (0.22, 1.43)	0.23
Liver	81	47		Reference	
Lung	4	7		0.08 (0.02, 0.36)	0.001
Multivisceral	7	11		0.47 (0.16, 1.36)	0.16
EBV Serology at Transplant					
D+/R+	57	29	0.001	3.90 (1.55, 9.80)	0.004
D+/R-	60	28		4.83 (2.02, 11.55)	0.0005
D-/R+	15	15		2.48 (0.85, 7.19)	0.096
D-/R-	12	26		Reference	
Unknown	16	13		2.50 (0.87, 7.17)	0.089
Age at Transplant					
	Median (IQR)	Median (IQR)			
Age at Transplant	5.6 (0.8, 15.1)	4.1 (0.8, 13.8)		1.10 (1.04, 1.16) (Per Every One Year Increase)	0.0005

163

164 An analysis of the geometric mean of the highest value of EBV DNAemia (Table 5) showed that in the
165 unadjusted model, liver transplant recipients had a higher geometric mean of the maximum EBV value
166 79.8 units/uL (95% CI 47-135.5) compared to heart transplant recipients at 14.6 units/uL (95% CI 6.6-
167 32.1), and kidney transplant recipients 8.6 units/uL (95% CI 3.3-22.6), p=0.007 and p<0.001 respectively.
168 In the adjusted model, liver transplant recipients had a higher geometric mean of the maximum EBV

169 value at 53 units/ μ L (95% CI 26.3, 106.9) compared to intestinal transplant recipients at 6.4 units/ μ L
 170 (95% CI 1.2, 31.0), $p=0.005$. Lastly, children who developed PTLD had higher geometric mean values of
 171 EBV, 211.6 (56.7, 790.1) copies/ μ L, compared to children without PTLD, who had a geometric mean EBV
 172 value of 27.3 (18.0, 41.2) copies/ μ L ($p<0.0001$). Type of transplant was not significant in the adjusted
 173 model ($p=0.14$).

174 Table 5: The geometric mean maximum EBV value (Mean of Max EBV) in copies/ μ L is shown for
 175 each demographic group in an unadjusted model, and an adjusted model.

		Unadjusted Model			Adjusted Model		
		Mean of Max EBV	95% CI	p-value	Mean of Max EBV	95% CI	p-value
Type of Transplant							
	Heart	14.6	(6.6, 32.1)	0.007	39.8	(17.7, 89.5)	0.99
	Intestine	8.2	(1.2, 56.7)	0.224	6.4	(1.2, 31.0)	0.005
	Kidney	8.6	(3.3, 22.6)	<0.001	34.5	(13.3, 89.3)	0.17
	Liver	79.8	(47, 135.5)	Ref.	53	(26.3, 106.9)	Ref.
	Lung	7.4	(0.5, 114.7)	0.095	60	(5.0, 722.3)	0.5
	Multivisceral	50	(8.3, 300)	0.622	20.6	(4.4, 97.0)	0.58
EBV Serology at Transplant							
	D+/R+	11.2	(5.9, 21.2)	0.88	14.9	(6.5, 34.5)	0.605
	D+/R-	100.3	(54.1, 185.9)	0.056	62.8	(29.0, 136.0)	0.07
	D-/R+	42.9	(12.1, 152.5)	0.52	45.6	(13.4, 155.0)	0.26
	D-/R-	23.3	(5.9, 91.4)	Ref.	23.2	(6.3, 84.9)	Ref.
	Unknown	21.7	(6.6, 71)	0.94	20	(6.6, 60.9)	0.82
Age at Transplant (For every 1 year increase)		0.8	(0.76, 0.84)	<0.001	0.81	(0.76, 0.86)	<0.001
Induction Immunosuppression							
	ATG or High Dose Steroids	22.4	(8.5, 59.3)	Ref.	47	(17.5, 126.1)	Ref
	Not ATG or High Dose Steroids	34.1	(21.8, 53.3)	0.44	17.7	(9.32, 33.5)	0.1
PTLD							
	PTLD +	211.6	(56.7, 790.1)	Ref.	177.6	(58.6, 538.0)	Ref.

176	PTLD -	27.3	(18.0, 41.2)	<0.001	15.2	(7.4, 31.2)	<0.001
-----	--------	------	--------------	--------	------	-------------	--------

177 A final analysis was performed evaluating the association between risk factors and time to PTLD, and the
 178 adjusted analysis is included (Table 6). Every \log_{10} increase in maximum EBV value was associated with a
 179 hazards ratio (HR) of 2.18 for development of PTLD (95% CI 1.19-3.99, $p=0.02$). Transplant year was also
 180 significant in this analysis. For every one year increase in transplant year, there was a decrease in the
 181 hazard ratio, denoted at 0.71 (95% CI 0.53-0.95, $p=0.02$). Kidney transplant recipients also had higher
 182 hazards ratios for PTLD compared to liver transplant recipients, HR 6.15 (95% CI 1.36-27.73, $p=0.02$).
 183 There was also a trend toward association between type of induction immunosuppression, with ATG
 184 and high dose steroids, with a hazards ratio of 10.1 (95% CI 0.994-103.8, $p=0.0506$), which was just out
 185 of the range of significance.

186 Table 6: Adjusted hazards ratios (HR) for significant covariates for the outcome time to PTLD

Covariate	Reference	HR	95% CI	p-value	
EBV DNAemia level	For every \log_{10} increase in max level of EBV DNAemia	2.18	(1.19, 3.99)	0.02	
EBV Serology					
	D+/R+	D-/R-	0.37	(0.05, 2.92)	0.34
	D+/R-	D-/R-	0.21	(0.02, 3.00)	0.21
	D-/R+	D-/R-	N/A		
Type of Transplant					
	Heart Transplant	Liver Transplant	N/A		
	Intestine Transplant	Liver Transplant	1.34	(0.29, 6.25)	0.72
	Kidney Transplant	Liver Transplant	6.15	(1.36, 27.73)	0.02
	Lung Transplant	Liver Transplant	43.58	(0.97, 1957)	0.051
	Multivisceral Transplant	Liver Transplant	0.2	(0.01, 2.93)	0.24
Transplant Year					
	For every year increase	0.71	(0.53, 0.95)	0.02	
Age at transplant (years)					
		0.98	(0.85, 1.13)	0.78	

Induction Immunosuppression	ATG or high dose steroids	No T-cell depleting agents	10.1	(0.994, 103.8)	0.0506

187

188 Discussion

189 This is the first study to fully describe characteristics of post-transplant EBV DNAemia in the pediatric
190 solid organ transplant population. In our analysis of 275 SOT pediatric recipients, type of transplant and
191 race were significantly associated with higher risk for PTLD. Intestinal and multivisceral transplant
192 recipients had the highest risk of developing PTLD, which is supported by the literature. We interpret
193 the findings of race with caution, as the overall sample size is small, and only two out of four Asians with
194 EBV DNAemia developed PTLD. We were unable to find any other risk factors that were significantly
195 associated with PTLD in our population, including type of induction immunosuppression or age. This may
196 have been due to distinctions within our population or to limited sample size.

197 When we examine risk factors for EBV DNAemia, and for magnitude of EBV DNAemia, some common
198 themes emerge. For EBV DNAemia, EBV serologies of the donor and the recipient are an obvious risk
199 factor. Age is also a practical risk factor as the risk of being exposed to EBV increases with age. Type of
200 transplant is not associated with risk of EBV DNAemia in the adjusted model, but within the category,
201 we see that EBV DNAemia tended to be more common in liver transplant recipients.

202 Age was the most resilient predictor for the maximum height of EBV DNAemia, as it changed the least
203 from the unadjusted to the adjusted model. Intestinal transplants did not have a significantly different
204 height of EBV DNAemia, yet they still had a higher risk association with PTLD, which suggests that other
205 factors such as length and duration of immunosuppression should be considered. Ultimately, those who
206 developed PTLD had significantly higher maximum levels of EBV DNAemia, which has been seen in
207 previous studies.⁵ However, stratifying by type of transplant does matter; liver transplant recipients

208 were more likely to have a higher maximum level of DNAemia compared to heart and intestinal
209 transplant recipients but were not more likely to develop PTLD.

210 Our final analysis is significant in that higher levels of EBV DNAemia are associated with decreased time
211 to PTLD, even when adjusted for other risk factors. It is also important to note that an earlier date of
212 transplant was associated with a higher hazards ratio for PTLD. This may have been due to better EBV
213 monitoring over time and the development of protocols which have standardized practice at our center.
214 The significance of a higher hazards ratio for kidney transplants is not clear at this time, but may reflect
215 ongoing immunosuppression practices at our center. Lastly, type of induction immunosuppression may
216 be important given the trend towards decreased time to PTLD with the use of alemtuzumab, ATG, or
217 high dose steroids. These findings may help with stratifying patients who may be at higher risk for PTLD.

218 All pediatric SOT studies for PTLD and EBV are limited by small sample sizes and this single center study
219 is no exception. The overall incidence of PTLD was relatively low. This may have be due to the quick
220 responsiveness of clinicians to high EBV levels. One major limitation is that we were unable to adjust for
221 time-varying exposures to immunosuppressive medications. Higher periods of immunosuppression
222 could have led to increased incidence of PTLD, EBV DNAemia, and higher maximum EBV levels. We did
223 have access to a wealth of data due to frequent EBV monitoring and were able to examine multiple risk
224 factors for EBV DNAemia and the maximum height of EBV DNAemia. However, this study was not
225 adequately powered to examine the numerous interactions between risk factors that may occur in
226 predicting PTLD. Further prospective or multicenter studies are needed to link significant clinical factors
227 and EBV DNAemia with PTLD and other clinical outcomes.

228

229 Conclusion

230 Type of transplant and age were associated with PTLD in pediatric SOT recipients. Age and EBV donor
231 and recipient serology remain key risk factors in the development of EBV DNAemia and the maximum
232 height of EBV DNAemia. Maximum level of EBV DNAemia, year of transplant, and possibly induction
233 regimens were associated with time to PTLD in our population. While this study has shed some light on
234 risk factors for EBV DNAemia in pediatric SOT recipients, further studies are needed in order to fully
235 characterize the relationship between EBV levels and PTLD.

236

237 Acknowledgments: None

References

1. Allen UD, Preiksaitis JK, AST Community of Practice. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant* 2019;33(9): e13652. PMID 31230381
2. Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. *Am J Transplant* 2013;13 Suppl 3:41-54. PMID 23347213
3. San-Juan R, Manuel O, Hirsch HH, Fernández-Ruiz M, López-Medrano F, Comoli P, et al. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey. *Clin Microbiol Infect* 2015;21(6): 604. PMID: 25686696
4. Green M, Webber S. Posttransplantation lymphoproliferative disorders. *Pediatr Clin North Am* 2003;50(6): 1471-91. PMID: 14710788
5. Allen UD, Farkas G, Hébert D, Weitzman S, Stephens D, Petric M, et al. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study. *Pediatr Transplant* 2005;9(4): 450-5. PMID 16048596.
6. Weintraub L, Weiner C, Miloh T, Tomaino J, Joashi U, Benchimol C, et al. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia. *J Pediatr Hematol Oncol*. 2014;36(8): e481-6. PMID: 24878618
7. Bingler MA, Feingold B, Miller SA, Quivers E, Michaels MG, Green M et al. Chronic High Epstein-Barr Viral Load State and Risk for Late-Onset Posttransplant Lymphoproliferative Disease/Lymphoma in Children. *Am J Transplant*. 2008;8(2): 442-5. PMID: 18211510

8. Lau AH, Soltys K, Sindhi RK, Bond G, Mazariegos GV, Green M. Chronic high Epstein-Barr viral load carriage in pediatric small bowel transplant recipients. *Pediatr Transplant* 2010;14(4): 549-53. PMID: 20102529
9. Green M, Soltys K, Rowe DT, Webber SA, Mazareigos G. Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients. *Pediatr Transplant* 2009;13(3): 319-23. PMID: 18397216
10. Yamada M, Nguyen C, Fadakar P, Ganoza A, Humar A, Shapiro R, et al. Epidemiology and outcome of chronic high Epstein-Barr viral load carriage in pediatric kidney transplant recipients. *Pediatr Transplant* 2018;22(3): e13147. PMID: 29411474
11. Fellner MD, Durand KA, Solernou V, Bosaleh A, Balbarrey Z, García de Dávila MT, et al. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders. *Rev Argent Microbiol.* 201;48(2): 110-8. PMID: 27157146.
12. Colombini E, Guzzo I, Morolli F, Longo G, Russo C, Lombardi A, et al. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients. *Pediatr Nephrol.* 2017;32(8): 1433-1442. PMID: 28280938.
13. Narkewicz MR, Green M, Dunn S, Millis M, McDiarmid S, Mazariegos G, et al. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience. *Liver Transpl* 2013;19(7): 730-40. PMID: 23696264
14. Chinnock R, Webber SA, Dipchand AI, Brown RN, George JF, Pediatric Heart Transplant Study. A 16-year multi-institutional study of the role of age and EBV status on PTLTD incidence among pediatric heart transplant recipients. *Am J Transplant* 2012;12: 3061- 3068. PMID: 23072522
15. Horvath MM, Winfield S, Evans S, Slopek S, Shang H, Ferranti J. The DEDUCE Guided Query tool: providing simplified access to clinical data for research and quality improvement. *J Biomed Inform* 2011; 44:266–76.

16. Niesters HG, Van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus AD. Development of a Real-Time Quantitative Assay for Detection of Epstein-Barr Virus. *J Clin Microbiol* 2000;38(2):712-5.
PMID: 10655372
17. Stevens SJ, Vervoort MB, van den Brule AJ, Meenhorst PL, Meijer CJ, Middeldorp JM. Monitoring of Epstein-Barr Virus DNA Load in Peripheral Blood by Quantitative Competitive PCR. *J Clin Microbiol* 1999;37(9): 2852–2857. PMID: 10449464